Petros Pharmaceuticals, Inc. (PTPI)
| Previous Close | 0.7133 |
| Open | 0.7000 |
| Bid | 0.6532 x 100 |
| Ask | 0.7366 x 100 |
| Day's Range | 0.6840 - 0.7200 |
| 52 Week Range | 0.6020 - 5.2400 |
| Volume | |
| Avg. Volume | 798,318 |
| Market Cap | 4.758M |
| Beta (5Y Monthly) | 2.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.3500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
ACCESSWIREPetros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
Collaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED patients(Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 23, 2024 / Petros Pharmaceuticals, Inc. ...
- ACCESSWIRE
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
(Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ...
- ACCESSWIRE
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% of all users) underscoring the significant potential ...
